Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Apexigen Inc. had its IPO on 2021-06-17 under the ticker symbol APGNW.
The company operates in the Healthcare sector and Biotechnology industry. Apexigen Inc. has a staff strength of 27 employees.
Shares of Apexigen Inc. opened at $0.05 at the start of the last trading session i.e. 2023-03-28.
The stocks traded within a range of $0.05 - $0.07, and closed at $0.07.
This is a -8.89% slip from the previous day's closing price.
A total volume of 1,204 shares were traded at the close of the day’s session.
In the last one week, shares of Apexigen Inc. have increased by +0.92%.
Apexigen Inc.'s Key Ratios
Apexigen Inc. has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Apexigen Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32538000. The EBITDA ratio measures Apexigen Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Apexigen Inc.’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q4, Apexigen Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Apexigen Inc.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Apexigen Inc.’s profitability.
Apexigen Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Apexigen Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.86 million
- Total Liabilities
- $16.47 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Apexigen Inc. ended 2023 with $22.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.86 million while shareholder equity stood at $6.38 million.
Apexigen Inc. ended 2023 with $0 in deferred long-term liabilities, $16.47 million in other current liabilities, 2000.00 in common stock, $-176793000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.80 million and cash and short-term investments were $16.80 million. The company’s total short-term debt was $106,000 while long-term debt stood at $0.
Apexigen Inc.’s total current assets stands at $21.19 million while long-term investments were $0 and short-term investments were $2.00 million. Its net receivables were $0 compared to accounts payable of $5.34 million and inventory worth $0.
In 2023, Apexigen Inc.'s operating cash flow was $0 while its capital expenditure stood at $14000.
Comparatively, Apexigen Inc. paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Apexigen Inc. stock is currently trading at $0.07 per share. It touched a 52-week high of $0.876 and a 52-week low of $0.876. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.09 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Apexigen Inc.
Similar Industry Stocks (Biotechnology)
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.